These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 26763419)

  • 21. Rationale for targeting the PI3K/Akt/mTOR pathway in myeloproliferative neoplasms.
    Bartalucci N; Guglielmelli P; Vannucchi AM
    Clin Lymphoma Myeloma Leuk; 2013 Sep; 13 Suppl 2():S307-9. PubMed ID: 24290217
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PLC and PI3K/Akt/mTOR signalling in disease and cancer.
    Follo MY; Manzoli L; Poli A; McCubrey JA; Cocco L
    Adv Biol Regul; 2015 Jan; 57():10-6. PubMed ID: 25482988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Gene Expression Status of the PI3K/AKT/mTOR Pathway in Gastric Cancer Tissues and Cell Lines.
    Riquelme I; Tapia O; Espinoza JA; Leal P; Buchegger K; Sandoval A; Bizama C; Araya JC; Peek RM; Roa JC
    Pathol Oncol Res; 2016 Oct; 22(4):797-805. PubMed ID: 27156070
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The comparison between dual inhibition of mTOR with MAPK and PI3K signaling pathways in KRAS mutant NSCLC cell lines.
    Dogan Turacli I; Ozkan AC; Ekmekci A
    Tumour Biol; 2015 Dec; 36(12):9339-45. PubMed ID: 26108998
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pan-Cancer Analysis Pinpoints Targets in PI3K Pathway.
    Cancer Discov; 2017 Aug; 7(8):OF6. PubMed ID: 28619980
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PI3K/AKT Pathway and Its Mediators in Thyroid Carcinomas.
    Nozhat Z; Hedayati M
    Mol Diagn Ther; 2016 Feb; 20(1):13-26. PubMed ID: 26597586
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Megalencephaly and hemimegalencephaly: breakthroughs in molecular etiology.
    Mirzaa GM; Poduri A
    Am J Med Genet C Semin Med Genet; 2014 Jun; 166C(2):156-72. PubMed ID: 24888963
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [PI3K and mTOR pathway and molecular targeted agents].
    Nishio K; Sakai K; Togashi Y
    Nihon Rinsho; 2015 Aug; 73(8):1315-22. PubMed ID: 26281684
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic variants in PI3K/Akt/mTOR pathway genes contribute to gastric cancer risk.
    Ge Y; Liu H; Qiu X; Ma G; Wang H; Du M; Wang M; Zhao Q; Tao G; Chu H; Zhang Z
    Gene; 2018 Sep; 670():130-135. PubMed ID: 29802999
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting PI3K-AKT-mTOR by LY3023414 inhibits human skin squamous cell carcinoma cell growth in vitro and in vivo.
    Zou Y; Ge M; Wang X
    Biochem Biophys Res Commun; 2017 Aug; 490(2):385-392. PubMed ID: 28623128
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of PI3K-Akt-mTOR signal pathway dismissed the stimulation of glucose on goose liver cell growth.
    Wei S; Han C; He F; Song Q; Kang B; Liu H; Li L; Xu H; Zeng X
    J Anim Physiol Anim Nutr (Berl); 2017 Oct; 101(5):e133-e143. PubMed ID: 27859698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced cancer.
    Shimizu T; Tolcher AW; Papadopoulos KP; Beeram M; Rasco DW; Smith LS; Gunn S; Smetzer L; Mays TA; Kaiser B; Wick MJ; Alvarez C; Cavazos A; Mangold GL; Patnaik A
    Clin Cancer Res; 2012 Apr; 18(8):2316-25. PubMed ID: 22261800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PI3K-Akt-mTOR signal inhibition affects expression of genes related to endoplasmic reticulum stress.
    Song Q; Han CC; Xiong XP; He F; Gan W; Wei SH; Liu HH; Li L; Xu HY
    Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting RAS-MAPK-ERK and PI3K-AKT-mTOR signal transduction pathways to chemosensitize anaplastic thyroid carcinoma.
    Milosevic Z; Pesic M; Stankovic T; Dinic J; Milovanovic Z; Stojsic J; Dzodic R; Tanic N; Bankovic J
    Transl Res; 2014 Nov; 164(5):411-23. PubMed ID: 25016932
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effects of acupuncture on PI3K/Akt/mTOR signaling pathway in rats with premature ovarian failure].
    Zhang Y; Yu B; Chen J; Zhao Z; Wang Jiali ; Huang F; Lin Y; Wang M; Zhang Y; Wei B
    Zhongguo Zhen Jiu; 2015 Jan; 35(1):53-8. PubMed ID: 25906570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [EEF1A2 inhibits the p53 function in hepatocellular carcinoma via PI3K/AKT/mTOR-dependent stabilization of MDM4].
    Longerich T
    Pathologe; 2014 Nov; 35 Suppl 2():177-84. PubMed ID: 25394965
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical significance of genetic variations in the PI3K/PTEN/AKT/mTOR pathway in Korean patients with colorectal cancer.
    Kim JG; Chae YS; Sohn SK; Kang BW; Moon JH; Lee SJ; Jeon SW; Park JS; Park JY; Choi GS
    Oncology; 2010; 79(3-4):278-82. PubMed ID: 21412012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation Profiling of Usual Ductal Hyperplasia of the Breast Reveals Activating Mutations Predominantly at Different Levels of the PI3K/AKT/mTOR Pathway.
    Jahn SW; Kashofer K; Thüringer A; Abete L; Winter E; Eidenhammer S; Viertler C; Tavassoli F; Moinfar F
    Am J Pathol; 2016 Jan; 186(1):15-23. PubMed ID: 26718977
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.